Viewing Study NCT00549705


Ignite Creation Date: 2025-12-25 @ 3:24 AM
Ignite Modification Date: 2025-12-26 @ 2:04 AM
Study NCT ID: NCT00549705
Status: COMPLETED
Last Update Posted: 2009-09-17
First Post: 2007-10-24
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Registry of Hospitalized Patients Treated With Fondaparinux
Sponsor: Brigham and Women's Hospital
Organization:

Study Overview

Official Title: Registry of Hospitalized Patients Treated With Fondaparinux
Status: COMPLETED
Status Verified Date: 2009-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Registry of Hospitalized patients at Brigham and Women's Hospital treated with Fondaparinux
Detailed Description: The use of antithrombotic agents in the hospital is the mainstay of therapy for the treatment or prophylaxis of venous thromboembolism (VTE) and acute coronary syndrome (ACS). Concern with the administration of heparins and risk for adverse sequelae has led to the development of newer, longer-acting agents. Fondaparinux offers once daily administration with only an extremely small risk of developing heparin induced thrombocytopenia.

Recent data have further demonstrated the efficacy and safety of Fondaparinux in VTE and ACS, expanding its use in clinical practice. We aim to: 1) determine how Fondaparinux is being used in a "real life" clinical setting, a tertiary-care academic medical center (BWH), and 2) assess the associated clinical outcomes at 90 days after initiation of Fondaparinux.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: